A B S T R A C T Alveolar hypoxia causes pulmonary vasoconstriction; we investigated whether hypoxia could also impair pulmonary vasodilation. We found in the isolated perfused rat lung a delay in vasodilation following agonist-induced vasoconstriction. The delay was not due to erythrocyte or plasma factors, or to alterations in base-line lung perfusion pressure. Pretreating lungs with arachidonic acid abolished hypoxic vasoconstriction, but did not influence the hypoxiainduced impairment of vasodilation after angiotensin II, bradykinin, or serotonin pressor responses. Progressive slowing of vasodilation followed angiotensin IIinduced constriction as the lung oxygen tension fell progressively below 60 Torr. KCI, which is not metabolized by the lung, caused vasoconstriction; the subsequent vasodilation time was delayed during hypoxia. However, catecholamine depletion in the lungs abolished this hypoxic vasodilation delay after KCIinduced vasoconstriction. In lungs from high altitude rats, the hypoxia-induced vasodilation impairment after an angiotensin II pressor response was markedly less than it was in lungs from low altitude rats. We conclude from these studies that (a) hypoxia impairs vasodilation of rat lung vessels following constriction induced by angiotensin II, serotonin, bradykinin, or KCI, (b) hypoxia slows vasodilation following KCIinduced vasoconstriction probably by altering lung handling of norepinephrine, (c) the effect of hypoxia on vasodilation is not dependent on its constricting effect on lung vessels, (d) high altitude acclimation moderates the effect of acute hypoxia on vasodilation, and (e) the hypoxic impairment of vasodilation is possibly the result of an altered rate of dissociation of agonists from their membrane receptors on the vascular smooth muscle.
A B S T R A C T Alveolar hypoxia causes pulmonary vasoconstriction; we investigated whether hypoxia could also impair pulmonary vasodilation. We found in the isolated perfused rat lung a delay in vasodilation following agonist-induced vasoconstriction. The delay was not due to erythrocyte or plasma factors, or to alterations in base-line lung perfusion pressure. Pretreating lungs with arachidonic acid abolished hypoxic vasoconstriction, but did not influence the hypoxiainduced impairment of vasodilation after angiotensin II, bradykinin, or serotonin pressor responses. Progressive slowing of vasodilation followed angiotensin IIinduced constriction as the lung oxygen tension fell progressively below 60 Torr. KCI, which is not metabolized by the lung, caused vasoconstriction; the subsequent vasodilation time was delayed during hypoxia. However, catecholamine depletion in the lungs abolished this hypoxic vasodilation delay after KCIinduced vasoconstriction. In lungs from high altitude rats, the hypoxia-induced vasodilation impairment after an angiotensin II pressor response was markedly less than it was in lungs from low altitude rats. We conclude from these studies that (a) hypoxia impairs vasodilation of rat lung vessels following constriction induced by angiotensin II, serotonin, bradykinin, or KCI, (b) hypoxia slows vasodilation following KCI- induced vasoconstriction probably by altering lung handling of norepinephrine, (c) the effect of hypoxia on vasodilation is not dependent on its constricting effect on lung vessels, (d) high altitude acclimation moderates the effect of acute hypoxia on vasodilation, and (e) the hypoxic impairment of vasodilation is possibly the result of an altered rate of dissociation of agonists from their membrane receptors on the vascular smooth muscle.
INTRODUCTION
Alveolar hypoxia causes pulmonary arterial constriction and alters responses to vasoactive substances (1) .
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It is not known, however, whether hypoxia affects pulmonary vasodilation. Recent work indicated that low oxygen impaired femoral artery relaxation after constriction that was induced by acetylcholine (2) . Low oxygen also slowed isoproterenol-induced dilation of isolated arteries (3) . Thus, hypoxia slowed the relaxation of isolated systemic vessels. Because the availability of oxygen is a major controller of the pulmonary arterial bed, we wondered whether low oxygen would also slow relaxation in the pulmonary circulation. Recently, it was suggested that the controlling effect of oxygen on the pulmonary arterial bed is mediated by vasodilation (4) . Our preliminary experiments suggested that airway hypoxia in isolated rat lungs prolonged the time that was required for vasodilation after angiotensin II-induced vasoconstriction (5) . We needed, then, a systematic study of the effects of low oxygen on the ability of lung vessels to relax.
We knew that because the lung arteries have the unique property of constricting with hypoxia, it would be difficult to determine whether hypoxia had an independent action on the arterial relaxation. However, if we could abolish hypoxic vasoconstriction, but have a pulmonary arterial bed that would still constrict in response to a vasopressor agent, then we could study the effect ofhypoxia on the constriction and subsequent vasodilation in the absence ofhypoxic vasoconstriction. Such experiments could provide new insight into the roles of hypoxia in vascular control in the lung.
METHODS
Adult male Sprague-Dawley rats with an average weight of 350±30 g were used for the experiments. Following pentobarbital anesthesia (30 mg/kg i.p.) the lungs were isolated as described (6, 7) . The lungs were ventilated with 21% 02-5% C02-74% N2 by positive pressure and perfused at constant flow (0.03 ml/g body wt) with heparinized blood that had been collected from three donor rats. After an equilibration period of 30 min at 38°C, each lung was challenged with airway hypoxia (3% 02, 5% CO2, 92% N2) and angiotensin II (Sigma Chemical Co., St. Louis, Mo.) angiotensin II was injected as a bolus into the pulmonary artery line (all pulmonary arterial injections were of 0.1 ml vol) to assume normal vascular reactivity of the preparation. The pulmonary artery pressure was measured with a Statham transducer (Statham Instruments, Oxnard, Calif.) and recorded continuously on a Gilson recorder (Gilson Medical Electronics, Middleton, Wis.). For the angiotensin challenges, and challenges with other vasoconstricting agents, we measured the vasodilation time as the time required for the pulmonary artery pressure to return from the peak ofthe pressor response to halfway to base line, t = APap/2. Whenever vasodilation time was in excess of 240 s, we used this value for the statistical caleculations. Table I gives an overview of experiments.
Effects of hypoxia on pressor responses to angiotensioni IL. We measured the pressure rise and vasodilation time in response to 1 ,ug angiotensin II in seven blood-perfused rat lungs during normoxia (Pao2 133±3 Torr) and again 30 min later during the 6th min of a continuing hypoxic pressor response (Pao2 38±3 Torr, experiment 1). We then used three different maneuvers to determine whether base-line perfusion pressure had an effect on vasodilation time following angiotensin II pressor responses. (a) In two rat lungs (experiment 2) we observed the effect of angiotensin II injection before and after we raised the perfusion pressure by increasing the blood flow from 9 to 18 ml/min. (b) In two other rat lungs (experiment 3), we gave 1 ,ug angiotensin II at hourly intervals for 4 h, thus taking advantage of the slow increase in the base-line perfusion pressure with duration of perfusion. (c) In two experiments (experiment 4) we gave angiotensin II before and after the perfusion pressure was raised by the addition ofpotassium chloride to the blood reservoir.
In addition, in two rats (experiment 5) we gave increasing doses ofangiotensin II (0.5, 1.0, and 1.5 ,ug) to see whether the magnitude of the pressor response, which also seems to determine the upstroke time, affected vasodilation time.
We wished to abolish the pulmonary pressor response to hypoxia, but not to angiotensin II. From a preliminary study, we knew that 5 jxg/ml of sodium arachidonate (Nucheck, Eliason, Minn.), added to the blood reservoir, abolished the hypoxic pressor response (5, 8) . To further characterize the effect of arachidonic acid on lung vasoconstriction, we added 5 ,ug/ml sodium arachidonate to the blood reservoir of six rat lungs during normoxia. Bolus injection of angiotensin II was tested before and after arachidonate addition (experiment 6). In seven rat lungs, 5 ,ug/ml sodium arachidonate was added to the blood reservoir during the plateau phase of a hypoxic pressor response (3% FiO2, experiment 7). The pressor responses to 3 and 0% Fio2 were measured within 60 min after arachidonate addition.
Effects of varying degrees of hypoxia and changes in perfusate on vasodilation time. In six blood-perfused rat lungs (experiment 8) we performed one hypoxic challenge (Fio2 3%) and one angiotensin II challenge. During the 6th min ofthe second hypoxic challenge, we gave the sodium arachidonate to the blood reservoir and observed the disappearance ofthe hypoxic pressor response. During subsequent hypoxic episodes, we gave angiotensin II 6 min after the ventilating gas was changed in random order from one containing 21% oxygen to a mixture containing either 7, 3, or 0% 02 in 5% Co2, Vasodilation time following serotonin-and bradykinininduced pulmonary vasoconstriction. To determine whether the hypoxia-induced delay ofvasodilation was specific for angiotensin, we observed (in the presence of arachidonate) the effect of close arterial injections of serotonin (100 gg of 5-hydroxytryptamine creatinine sulfate, Sigma Chemical Co.) in four blood-perfused rat lungs (experiment 11) during normoxia and hypoxia (0% 02), and of bradykinin (100 ,ug bradykinin triacetate, Sigma Chemical Co.) in four rat lungs (experiment 12) during normoxia and hypoxia.
Vasodilation time following bolus KCl injection in normal and catecholamine-depleted lungs. To test whether the hypoxia-induced delay of vasodilation could be observed with a pressor substance that is not metabolized during passage through the lung, we injected (in the presence of arachidonate) 15 mg (in 0.1 ml vol) KCI into the pulmonary arterial lines of six rat lungs (experiment 13) during normoxia. Because of KCl accumulation, each lung received only one injection of KCl. Thus, we gave KCl to six different rat lungs (experiment 14) during hypoxia (0% 02). Since potassium can release norepinephrine from endogenous stores, any delay in relaxation during hypoxia could be due to inhibition by hypoxia of norepinephrine re-uptake or metabolism. To test the effects of KCl apart from such metabolic influences, we evaluated the KCl response in lungs from rats treated to deplete catecholamine stores. We gave six rats (experiment 15) intraperitoneal 6-hydroxydopaminehydrobromide (Regis Chemical Co., Morton Grove, Ill.) 2 mg/kg on day 1, 5 mg/kg on day 2, and 10 mg/kg on day 3 -2 h before lung removal and perfusion. We observed the effects of KCI injection (in the presence of arachidonate) in two of these lungs during normoxia, and in two lungs during hypoxia. In the remaining two lungs we gave 2 mg of tyramine and observed no effect on pulmonary arterial pressure. Further, we gave six rats (experiment 16) intraperitoneal reserpine (Ciba-Geigy Corporation, Summit, N. J.) 5 mg/kg daily for 10 d (6). In four ofthe lungs (in the presence ofarachidonate) we observed the effects of the KCl injection during hypoxia (0% 02) only. In the two remaining lungs the addition of2 mg tyramine had no effect on pulmonary arterial pressure. By contrast, tyramine added to the reservoir of lungs from three untreated rats (experiment 17) increased the pulmonarv arterial pressure 5±1 mm Hg.
The angiotensin II injection could also release norepinephrine from lung tissue (9, 10) . We therefore performed experiments in four lungs (experiment 18) from rats pretreated with 6-hydroxydopamine and in two lungs from rats pretreated with reserpine (experiment 19) , in which angiotensin II rather than KCl was given during normoxia and hypoxia.
Vasodilation time followving angiotensin lI-induced constriction in lungs from lows and high altitude rats. Pressor responses to 1 ,tg angiotenin were measured (in the presence of arachidonate) during normoxia (21% 02) and hypoxia (3% and 0% 02) in lungs from three groups of rats: rats kept at the laboratory altitude of 1,600 m (experiment 20, n = 6), rats exposed for 3 d to a simulated altitude of 4,250 m (experiment 21, n = 4), and rats exposed for 5 wk to a simulated altitude of 4,250 m (experiment 22, n = 4). Statistical analysis. Data are displayed as mean±+SD. The Student's t test was used to evaluate significant differences between groups. When we wished multiple comparison of groups, we used a two-way analysis of variance and the Student-Newman-Keuls test. Differences were considered to be significant if P < 0.05.
RESULTS
Effects of hypoxia on pressor responses to angiotensin II. The pressor responses to bolus injection of 1 ug angiotensin II were comparable during normoxia (21±1 mm Hg) and during hypoxia (18+2 mm Hg) but the vasodilation time was longer during hypoxia than during normoxia (65±5 vs. 22±3 s) (Fig. 1) . However, because of hypoxic vasoconstriction, the angiotensin II response during hypoxia began from a higher base line and reached a higher peak pressure than during normoxia. Increasing the base-line perfusion pressure, either by prolonging the perfusion time or by raising the flow, prolonged vasodilation time (Fig. 2 ), but the prolongation was less than that caused by hypoxia. Raising the perfusion pressure by the addition ofKCI did not prolong the vasodilation time in response to angiotensin II during normoxia (Fig. 3) . Increasingly higher doses of angiotensin II raised the peak pressure and seemed to shorten the vasodilation time (Fig. 4) 4 Relationship between vasodilation time, t(Pap/2) and the maximum increase in pulmonary arterial pressure (APap) with angiotensin II injection in two isolated bloodperfused lungs. The boluses of angiotensin II in the doses shown were given into the pulmonary artery at 20-min intervals. ment 7). Vasodilation time increased when the Po2 of pulmonary venous blood fell to 60 Torr and increased sixfold at a Po2 of 25 Torr (Fig. 6 ). Angiotensin II responses during normoxia in this series of experiments showed no change of vasodilation time in comparison with the data obtained in these lungs before arachidonate had been added. Vasodilation time was not affected by removing cells and plasma (Fig. 7 , Table II , experiments 9 and 10).
Vasodilation timefollowing serotonin or bradykinininduced vasoconstriction. Vasodilation time was prolonged following serotonin or bradykinin-induced vasoconstriction during hypoxia (Fig. 8 , Table II , experiments 11 and 12). Valuies for vasodilation time during hypoxia were not calculated since complete vasodilation did not occur while hypoxia lasted. However, t = A Pap/2 was >240 s.
Vasodilation time followving bolus KCl injections in normal and catecholamine-depleted lungs. The boluses of KCI induced pressor responses that were similar in magnitude to those ofangiotensin II. Hypoxia slowed vasodilation after the KC1 induced constriction (Fig. 9 ) and the magnitude of the slowing was comparable to that observed after angiotensin II was administered. After catecholamine stores had been depleted by pretreating the rats with either 6-hydroxydopamine or reserpine, hypoxia no longer slowed relaxation after KCI induced constriction (Table III) .
In catecholamine-depleted lungs, the pressor response to angiotensin II was normal during normoxia and hypoxia. The subsequent vasodilation was prolonged by hypoxia (Table I) . Thus, the catecholamine depletion did not affect the contraction or relaxation when angiotensin II was given during normoxia or hypoxia.
Vasodilation time following angiotensin II-induced constriction in lungs from low; and high altitude rats. The pressor responses to angiotensin II were slightly (Table IV) (11) . However, the vasodilation time during hypoxia decreased with increasing duration of stay at high altitude (Fig. 10 , Table II , experiments [20] [21] [22] . The vasodilation times during normoxia and hypoxia in these low altitude rat lungs pretreated with arachidonate (Table IV) were similar to the values observed in the low altitude rat lungs not pretreated with arachidonate ( Fig. 1) . The values of Po2 were similar in the two groups.
DISCUSSION
In the present study we found that angiotensin II given to isolated perfused rat lungs during hypoxia caused the expected pressor response, but that subsequent vasodilation was delayed when compared with normoxic lungs. We then attempted to separate the constricting effect of hypoxia from a hypoxic impairment of vasodilation. During normoxia neither raising the perfusion pressure by increasing flow before administering angiotension II, nor varying the dose of angiotensin II to yield varying peak pressures produced the delayed vasodilation observed during hypoxia. These findings suggested that there was an effect of hypoxia that was independent of base-line or peak pressure. We then abolished the hypoxic pressor response by administering sodium arachidonate to the perfusate of the preparation (5, 8 Catecholamine depletion by 6-OH-dopamine pretreatment the concept that KCI released norepinephrine (22, 23) from the lung, and that hypoxia impaired subsequent norepinephrine catabolism or re-uptake. It is possible, therefore, that hypoxia had acted on the metabolism of a variety of vasoconstrictor substances to prolong their effect. However, since pulmonary removal of serotonin (24, 25) and norepinephrine (26, 27) has been shown to be overwhelmed by microgram doses of these substances, the transport systems were most likely exhausted by the doses necessary to achieve marked pulmonary vasoconstriction. Furthermore, ouabain (1 mM) and cooling of the lungs, both of which have been shown to decrease pulmonary serotonin and norepinephrine removal (28) (29) (30) Shown are the Po2 of the venous blood draining the lung, the pulmonary arterial perfusion pressure just before injection of angiotensin II (base-line pressure), the maximal increase in pressure with angiotensin II injection (APap) and the vasodilation time (t = APap/2). All lungs had been pretreated with arachidonic acid to abolish the hypoxic pressor response. n is the number of experiments. * Values differ (P < 0.05) from low altitude control values.
LOW ALTITUDE I l 1 3 DAYS AT HIGH ALTIT E t~~~~~~:t or any intracellular response subsequent to the agonistreceptor interaction, or both. We are intrigued by the possibility that hypoxia could alter agonist-receptor interactions because prolonged vasodilation during hypoxia was seen only with agonists that bind to specialized receptors; when KCl, which presumably causes cell calcium influx without binding or activation of a hormone receptor, was used, vasodilation in catecholamine-depleted lungs was not delayed during hypoxia.
In recent studies, we proposed that metabolic adaptations to hypoxia can occur with chronic exposure to high altitude. Such adaptation might account for the blunting of hypoxic vasoconstriction in lungs from high altitude acclimated rats (11, 32) . We expected and found that in lungs from rats exposed for several weeks to high altitude, hypoxia would also be less effective in prolonging vasodilation time after angiotensin-induced vasoconstriction. It is possible that some adaptation of cell membrane function or cell metabolism during high altitude residence allows a relatively rapid vasodilation of pulmonary arterial smooth muscle during hypoxia.
Our results indicate that moderate degrees ofalveolar hypoxia prolong the action of some pharmacologic vasoconstrictor suibstances on the pulmonary circulation in the absence of hypoxic vasoconstriction. We conclude that alveolar hypoxia probably impairs vasodilation because of interference with vascular muscle properties that adapt during high altitude residence and not because of impairment of the metabolic degradation of the vasoconstrictor agonists. Such hypoxia-induced delay of relaxation following a vasoconstriction has not previously been shown for lung vessels and might be considered as an action of hypoxia on the lung circulation apart from its known constrictor effect. 
